Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous: 50 to 5000 MBq/mL [1.4 to135 mCi/mL]) |
| Drug Class | Radioactive diagnostic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for Positron Emission Tomography (PET) imaging of the brain to estimate -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimers Disease (AD) and other causes of cognitive decline.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Florbetaben F18 ([^18F]FBB) showed inconsistent effectiveness in diagnosing transthyretin amyloidosis cardiomyopathy (ATTR-CM), with study findings indicating contradictory diagnostic results.
- Among other tracers, Carbon-11 Pittsburgh compound B ([(11)C]PIB) and Fluorine-18 Sodium Fluoride (Na[(18)F]F) demonstrated consistent diagnostic utility, with [(11)C]PIB effectively distinguishing transthyretin amyloidosis (ATTR) patients from controls and Na[(18)F]F reliably differentiating between ATTR-CM and cardiac light chain amyloidosis.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Neuraceq (florbetaben F18) Prescribing Information. | 2024 | Life Molecular Imaging Ltd., Warwick, United Kingdom |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review | 2023 | European Journal of Nuclear Medicine and Molecular Imaging |